Postoperative Pain Management Market
Postoperative Pain Management Market Study by Opioids, NSAIDs, Local Anesthetic, and Acetaminophen Sold through Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Clinics from 2024 to 2034
Analysis of Postoperative Pain Management Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Postoperative Pain Management Market Outlook (2024 to 2034)
Worldwide revenue from the postoperative pain management market is estimated to reach US$ 21.94 billion in 2024 and further increase at a CAGR of 3.7% to climb to US$ 31.66 billion by the end of 2034. The necessity for postoperative pain management drugs is increasing steadily as the number of surgeries being carried out across the world rises.
Post-surgery care is provided to patients after their surgery. Throughout this period, they receive medications to aid their recovery and minimize risks and complications. Following any surgery, patients experience shock and discomfort, requiring attentive care. These pain management medications not only promote recovery but also alleviate pain intensity.
The goal of postoperative pain control is to lessen the negative effects of acute postsurgical pain and facilitate the patient's return to normal function. Traditionally, opioid analgesics have been the primary treatment for acute postoperative pain. However, the increase in morbidity and mortality rates has prompted greater emphasis on postoperative pain management, leading to the overall expansion of the postoperative pain management market size.
Key Market Growth Drivers
- In today’s fast-paced world, individuals look for options providing quicker recovery to return to work; these postoperative pain management medications efficiently promote speedy healing, enabling patients to resume an active lifestyle.
- Elderly individuals, who have a diminished tolerance for pain, rely on postoperative pain management medications for rapid recovery and pain reduction, making them the target age group for suppliers of such drugs.
- These medications are available in various forms, including injections and oral formulations, providing patients with flexibility in choosing according to their preferences. This is boosting demand for postoperative pain management drugs.
- Pain management medications reduce the risk of further bodily harm, leading to a significant reduction in hospital stays and enabling patients to save on medical expenses, thus making these drugs popular across all income groups.
- Patients of all age groups can safely utilize these medications without experiencing adverse effects, facilitating suppliers' sales growth through partnerships with hospital pharmacies and clinics.
- With quick onset of action and pain relief, these drugs are widely utilized as painkillers after surgeries. Increase in the number of surgical procedures is set to drive postoperative pain management market growth during the forecast period.
- A variety of drugs, including opioids, NSAIDs, local anesthetics, and acetaminophen, have been introduced in the market, offering patients a diverse range of options based on their affordability.
| Report Attribute | Detail |
|---|---|
| Postoperative Pain Management Market Size (2024E) | US$ 21.94 Billion |
| Forecasted Market Value (2034F) | US$ 31.66 Billion |
| Global Market Growth Rate (2024 to 2034) | 3.7% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 3.9% CAGR |
| China Market Value (2034F) | US$ 1.84 Billion |
| North America Market Share (2024E) | 41.7% |
| East Asia Market Share (2034F) | 11.6% |
| Key Companies Profiled | Novartis AG; Allergan Plc; Teva Pharmaceutical Industries Ltd.; Mylan Inc; Purdue Pharma L.P.; Janssen Pharmaceuticals Inc; Endo International Plc; Pacira Pharmaceuticals Inc.; Egalet Corporation; GlaxoSmithKline Plc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Postoperative Pain Management Market Trends are Significant for Suppliers?
“Rising Awareness of Palliative Care and Increase in Number of Road Accidents”
Rising prevalence of chronic diseases, a growing number of surgeries, the increasing need for innovative non-opioid analgesics in postoperative pain therapy, and heightened awareness of palliative care are all contributing to the demand for postoperative pain treatment procedures. The rising demand for pain-relief medications is also driving market expansion.
- As per National Health Statistics, there are 100 million surgeries conducted annually in the United States.
Increasing global surgery rates primarily lead to the extensive use of pain relief medications. Similarly, the rising incidence of pain associated with cancer therapy and the expanding demographics of pediatric and elderly patients undergoing diverse surgical interventions are fostering market growth.
Escalating number of road accidents is projected to coincide with the expansion of vehicle numbers in the coming years. A disregard for traffic regulations among drivers is also expected to contribute to road accidents. The rise in traffic accidents, consequent traumatic injuries, and the demand for pain management post-surgeries are poised to steer future demand for postoperative pain management.
These accidents inflict considerable suffering on patients if not promptly and effectively addressed. Nonetheless, effective postoperative pain management proves beneficial in mitigating intense pain and discomfort. Pain medications are poised to become more readily accessible for such road accidents, prompting key market players to ramp up production, ultimately fostering positive market growth.
Adoption of pain-relieving medications is gaining traction as major companies focus on introducing abuse-resistant opioid medications and extended-release non-opioid therapies for postoperative pain management. The increasing number of discoveries and commercialization of non-narcotic drugs, along with growing awareness of post-surgical pain management, are fueling market expansion.
What is Limiting Growth Opportunities for Postoperative Pain Management Drug Suppliers?
“Growing Concerns about Opioid Addiction and Rising Cost Burden on Reimbursement Providers”
Growing concerns about opioid addiction, as well as the rising cost burden of pain management on reimbursement providers, are expected to limit market expansion to some extent. Other factors limiting the market in Asia and Africa include adverse side effects from excessive NSAID and opioid use, as well as a scarcity of postoperative pain management drugs. For example, excessive morphine consumption can cause severe respiratory damage, including coma and death. Long-term morphine use can lead to psychological and physical addiction, as well as significant immune system damage.
Increased prevalence of drug abuse, combined with the addictive nature of opioids, has reduced the use of opioid prescriptions in developed countries. This has resulted in a decrease in opioid consumption for pain management, potentially affecting market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
According to Fact.MR, the market in South Korea is evaluated to expand at a moderate CAGR of 2.8% from 2024 to 2034, and the country is set to occupy a postoperative pain management market share of 11.2% in the East Asia region in 2024.
What are the Opportunities for Pain Management Drug Manufacturers in the United States?
“Strong Drug Pipeline with Pending FDA Approvals for Effective Postoperative Pain Medications”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 7.79 Billion |
| Growth Rate (2024 to 2034) | 4.1% CAGR |
| Projected Value (2034F) | US$ 11.62 Billion |
Use of postoperative pain medications is expected to increase in the United States due to a strong drug pipeline that includes effective medications awaiting FDA approval. Patients' attitudes have shifted in the United States as a result of greater adherence to pain treatment recommendations. The United States accounts for 85.2% share of the postoperative pain management market in North America in 2024.
Adoption of opioid treatment is expected to reduce the prevalence of the opioid epidemic in North America, particularly in the United States.
- In May 2021, Allay Therapeutics, a clinical-stage biotechnology company that has been at the forefront of developing ultra-sustained analgesic products to revolutionize postsurgical pain management and recovery, published the first-ever clinical data demonstrating non-opioid pain relief lasting two weeks after a single administration.
Why are Pain Management Drug Manufacturers Directing Their Distribution Efforts toward China?
“Robust Pharmaceutical Manufacturing Base”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 1.23 Billion |
| Growth Rate (2024 to 2034) | 4.1% CAGR |
| Projected Value (2034F) | US$ 1.84 Billion |
Several pain management drug manufacturers are entering into distribution agreements and partnerships, and launching postoperative pain management medications in the Asia Pacific region, especially in China. China’s robust pharmaceutical manufacturing capabilities are driving demand for postoperative pain management medications.
- For example, on May 1, 2018, Grunenthal signed a distribution and license agreement with Mundipharma, which authorized Mundipharma to promote and distribute Grunenthal's Tramal (tramadol) in China.
Category-wise Evaluation
Based on distribution channel, retail pharmacies are set to account for a significant market share of 39.6% in 2024.
Which Drug Class Finds Widespread Adoption for Postoperative Pain Management?
“Preference for Opioids Due to Their Instant Action in Reducing Pain”
| Attribute | Opioids |
|---|---|
| Segment Value (2024E) | US$ 11 Billion |
| Growth Rate (2024 to 2034) | 2.2% CAGR |
| Projected Value (2034F) | US$ 13.7 Billion |
Opioids are predominantly used to reduce pain after surgery. These drugs work by binding to specific receptors in the brain and nervous system to block pain signals and reduce pain sensation. Opioids excel in managing acute pain, which occurs immediately after a surgical procedure.
Which Administration Route is Generally Preferred by Patients?
“Ease of Use and Non-invasiveness of Oral Medications”
| Attribute | Oral |
|---|---|
| Segment Value (2024E) | US$ 8.51 Billion |
| Growth Rate (2024 to 2034) | 3.9% CAGR |
| Projected Value (2034F) | US$ 12.46 Billion |
The oral route of administration remains popular for postoperative pain management due to its ease of use and convenience. Oral medication is not invasive, unlike injections, making it a preferable option for patients. In addition, oral medication can be taken in home settings, and this reduces the need for hospital stays. Patients are seeking methods to recover in the comfort of their own homes.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Market Competition
Key players in the postoperative pain management market are acquiring other smaller pharmaceutical companies to develop new product lines of pain medications and adapting themselves to evolving market trends, such as neuropathic pain treatment.
- For example, Zyla Life Sciences acquired Assertio Therapeutics, Inc. in May 2020 to expand its product portfolio in the neurology, inflammation, and pain products divisions.
Fact.MR provides detailed information about the price points of key postoperative pain management drug providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.
Key Segments of Postoperative Pain Management Market Research
-
By Drug Class :
- Opioids
- NSAIDs
- Local Anesthetic
- Acetaminophen
-
By Route of Administration :
- Injectable
- Oral
- Tropical
- Transdermal
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Clinics
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Drug Class 6.2. Route of Administration 6.3. Distribution Channel 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class 7.1. Opioids 7.2. NSAIDs 7.3. Local Anesthetic 7.4. Acetaminophen 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration 8.1. Injectable 8.2. Oral 8.3. Tropical 8.4. Transdermal 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel 9.1. Hospital Pharmacies 9.2. Retail Pharmacies 9.3. Drug Stores 9.4. Clinics 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. East Asia 10.6. South Asia & Pacific 10.7. Middle East & Africa 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Sales Forecast 2024 to 2034 by Drug Class, Route of Administration, Distribution Channel, and Region for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Novartis AG 20.2. Allergan Plc 20.3. Teva Pharmaceutical Industries Ltd. 20.4. Mylan Inc 20.5. Purdue Pharma L.P. 20.6. Janssen Pharmaceuticals Inc 20.7. Endo International Plc 20.8. Pacira Pharmaceuticals Inc. 20.9. Egalet Corporation 20.10. GlaxoSmithKline Plc 21. Assumptions and Acronyms Drug Classd 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the postoperative pain management market in 2024?
The global market for postoperative pain management is estimated at US$ 21.94 billion in 2024.
What is the estimated CAGR for the postoperative pain management market?
The market for postoperative pain management is foreseen to advance at a CAGR of 3.7% between 2024 and 2034.
What portion of the North American market does Canada occupy?
Canada is forecasted to hold 11.4% share of the North American market by 2034.
What is the demand projection for post-surgery pain management drugs for 2034?
Worldwide revenue from the sales of post-surgery pain management drugs is projected to reach US$ 31.66 billion by 2034.
How fast is the market projected to expand in South Korea?
The market in South Korea is forecasted to expand at 2.8% CAGR through 2034.
Who are the leading players in the market?
Leading market players are Novartis AG, Allergan Plc, and Teva Pharmaceutical Industries Ltd.
What are the estimated sales of opioid drugs?
Revenue from the sales of opioid drugs is estimated to reach US$ 11 billion in 2024.
Postoperative Pain Management Market